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Abstract
Background: Large scale administration of the anthelminthic drug praziquantel (PZQ) to at-risk populations is the
cornerstone of schistosomiasis control, although persisting high prevalence of infections in some areas and
growing concerns of PZQ resistance have revealed the limitations of this strategy. Most studies assessing PZQ
efficacy have used relatively insensitive parasitological diagnostics, such as the Kato-Katz (KK) and urine-filtration
methods, thereby overestimating cure rates (CRs). This study aims to determine the efficacy of repeated PZQ
treatments against Schistosoma mansoni infection in school-aged children in Côte d’Ivoire using the traditional KK
technique, as well as more sensitive antigen- and DNA-detection methods.
Methods: An open-label, randomised controlled trial will be conducted in school-aged children (5 to 18 years) from the
region of Taabo, Côte d’Ivoire, an area endemic for S. mansoni. This 8-week trial includes four two-weekly standard doses of
PZQ in the “intense treatment” intervention group and one standard dose of PZQ in the “standard treatment” control group.
The efficacy of PZQ will be evaluated in stool samples using the KK technique and real-time PCR as well as in urine using
the point-of-care circulating cathodic antigen test and the up-converting phosphor, lateral flow, circulating anodic antigen
assay. The primary outcome of the study will be the difference in CR of intense versus standard treatment with PZQ on
individuals with a confirmed S. mansoni infection measured by KK. Secondary outcomes include the difference in CR and
intensity reduction rate between the intense and standard treatment groups as measured by the other diagnostic tests, as
well as the accuracy of the different diagnostic tests, and the safety of PZQ.
Discussion: This study will provide data on the efficacy of repeated PZQ treatment on the clearance of S. mansoni as
measured by several diagnostic techniques. These findings will inform future mass drug administration policy and shed light
on position of novel diagnostic tools to evaluate schistosomiasis control strategies.
Trial registration: The study is registered at EudraCT (2016–003017-10, date of registration: 22 July 2016) and (NCT02868385,
date of registration: 16 August 2016).
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Background
Schistosomiasis is still a major public health problem in
many tropical countries, particularly in Africa where
more than 90% of the global burden of schistosomiasis
occurs [1]. Large-scale administration of the anthel-
minthic drug praziquantel (PZQ) to at-risk populations
has become the cornerstone of schistosomiasis control
[2, 3]. This strategy – known as preventive chemother-
apy – has been successful in reducing infection inten-
sities, and hence morbidity [4, 5]. As morbidity is a
result of cumulative exposure to a high number of schis-
tosomes, school-aged children bear the largest burden of
disease because they carry the highest intensity infec-
tions [6]. Therefore, mass drug administration (MDA) of
preventive chemotherapy targets school-aged children
primarily [6, 7]. These children are intermittently treated
with a single oral dose of 40 mg/kg PZQ, the frequency
of which depends on the prevalence of the infection in
the community [8]. Target populations are divided into
high-, moderate- and low-risk communities in which
school-aged children are treated with PZQ once a year,
once every 2 years or twice during their primary school-
ing age, respectively [9]. PZQ is the drug of choice for
the treatment of all forms of schistosomiasis due to its
high efficacy and excellent safety profile [10].
Observed cure rates (CRs) after a single dose of PZQ
treatment (40 mg/kg) range between 42 and 79% for
Schistosoma mansoni and between 37 and 93% for S.hae-
matobium in school-aged children [11]. A second dose
of PZQ at a later time point can increase the CR up to
93% for S.mansoni [11–13] and up to 99% for S. haema-
tobium [11]. However, the estimated efficacy of PZQ is
highly dependent on the diagnostic tool used to measure
CRs. Most studies have used traditional parasitological
methods, such as the Kato-Katz (KK) and urine-filtration
(UF) methods based on microscopy and determining the
presence/excretion of eggs. These methods lack sensitiv-
ity for diagnosing low level infections and as such over-
estimate CRs [14, 15]. More sensitive diagnostic tools
for schistosomiasis which are currently available and can
be implemented in the field, are much more suited to
evaluate the efficacy of PZQ and alternative dose regi-
mens. For example, the commercially available
point-of-care circulating cathodic antigen (POC-CCA)
test, which indicates active worm infection by detection
of parasite CCA in urine, has shown a high diagnostic
accuracy for S.mansoni with a sensitivity ranging be-
tween 78 and 92% and specificity approaching 100%
[15–17]. Over the past 10 years, this test has been widely
evaluated in sub-Saharan Africa and is now
recommended as the first line diagnostic to map schisto-
some prevalence and facilitate preventive chemotherapy
strategic decision-making [7, 16, 18]. In addition, there
is a pressing need for ultra-sensitive diagnostic tools for
areas where prevalence and infection intensity have been
reduced to very low levels. Such diagnostic tools are
needed to confirm interruption of transmission and
possibly elimination of schistosomiasis. The circulating
anodic antigen (CAA) detection assay fulfills these
requirements. This assay measures parasite antigen both
in urine and serum using an ultrasensitive reporter
technology (up-converting phosphor particles, UCP) in
combination with common immunochromatography,
lateral flow (LF). This UCP-LF CAA assay has shown
high sensitivity and specificity for all four main schisto-
some species (S.haematobium, S.japonicum, S.mansoni
and S.mekongi) [19–22]. In addition to the UCP-LF
CAA assay, highly specific and sensitive molecular poly-
merase chain reaction (PCR) techniques that detect
parasite-specific DNA in stool and urine have also be-
come available [16]. The combination of worm-derived
antigens and egg-derived nucleic acids, are envisaged to
further increase the sensitivity and specificity of the
diagnostic toolbox and allow for a comprehensive assess-
ment of PZQ efficacy, with respect to both parasite
worm dynamics and fecundity.
Rationale
There is a need for a re-evaluation of previously estab-
lished PZQ CRs to provide evidence for continuing mass
distribution of PZQ in high risk communities. Previ-
ously, CRs may have been overestimated due to insensi-
tive diagnostic tools, whereas continuing reinfections
and the fact that PZQ has little activity on immature
worms, might have led to an underestimation of the
therapeutic effect [23–26]. Repeated treatment with
PZQ at short intervals (e.g. 2–8 weeks) in areas with on-
going transmission will more effectively target
non-susceptible schistosomula as they will have matured
into drug susceptible worms during this period [11, 27],
thereby increasing the drug effectiveness. As the short
metabolic half-life of PZQ may also limit its effectiveness
by suboptimal plasma levels, repeated dosing will in-
crease the chance that all worms are affected [28].
Whether this will be reflected in a significant decrease in
schistosome prevalence and the potential to interrupt
transmission, remains to be investigated [11, 15, 29]. In
this study, we will evaluate the effect of multiple doses
of PZQ on parasite clearance and tolerance in individ-
uals infected with S.mansoni.
The primary objective of this study is to determine the
efficacy of PZQ treatment for clearing S.mansoni infec-
tions in a multiple dose regimen (standard dose, four
times, two-week intervals) using the KK technique. Sec-
ondary objectives include determining the efficacy of
PZQ for clearing S.mansoni infections in a multiple dose
regimen using DNA- and antigen-detection techniques,
evaluation the safety of PZQ and determining the
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accuracy of the different diagnostic tests used in this
study. Exploratory objectives include modelling the ef-
fect of multiple PZQ treatments on the transmission of
schistosomiasis as well as modelling the biological ef-
fects of multiple PZQ treatments on individual worm
burden, egg load and re-infection rates.
Methods
Study design
To evaluate the repeated doses of PZQ in schistosomiasis
treatment (RePST), an open-label, randomised controlled
trial will be conducted, with the primary aim to compare
the efficacy of one versus four doses of PZQ in S. mansoni
infected school-aged children in Côte d’Ivoire, using the
traditional KK thick smear technique as well as with more
sensitive antigen- and DNA-detection methods (Fig. 1).
After screening for eligibility, participants are randomised
into two groups in a 1:1 ratio. Individuals assigned to the
standard treatment group will receive a single dose of
PZQ (40mg/kg) at baseline (week 0) and will receive no
further treatment until the final visit. Individuals assigned
to the intense treatment group will receive four doses of
PZQ at baseline (week 0) and at three other time points
with 2-week intervals. Follow-up and sample collection
will take place every week for a period of eight weeks. At
the end of the study, all children from selected communi-
ties (including study participants) will be offered a stand-
ard dose of PZQ (single oral dose of 40mg/kg) as well as
albendazole (single oral dose of 400mg) according to
international guidelines of the World Health Organization
(WHO), in coordination with the National Control
Programme of Côte d’Ivoire (Programme National de
Lutte contre les Maladies Tropicales Négligées à Chi-
miothérapie Préventive, PNLMTN-CP), for the treatment of
schistosomiasis and soil-transmitted helminth infections,
respectively.
Study area and population
The study population will consist of school-aged chil-
dren (5 to 18 years) from selected villages of Singrobo,
Ahouaty and N’Denou in the Taabo health district,
south-central Côte d’Ivoire. This district is part of the
Taabo health and demographic surveillance system
(HDSS) and is located approximately 150 km north of
Abidjan and has been described in more detail previ-
ously [30, 31]. It comprises a small town, 13 villages and
Fig. 1 Flow-diagram
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over 100 hamlets, with a total population of 42.480 in-
habitants in 2013. The Taabo HDSS focuses, among
other things, on neglected tropical diseases such as
schistosomiasis and soil-transmitted helminths. Re-
peated cross-sectional epidemiological surveys on ap-
proximately 5–7% of the population and specific,
layered-on haematological, parasitological and ques-
tionnaire surveys have been regularly conducted every
year since 2009 within the Taabo HDSS [30].
Inclusion criteria
In order to be eligible to participate in this study, an in-
dividual must meet the following criteria:
– provide oral and signed assent as well as written
informed consent signed by parents/legal guardian(s)
– have a confirmed S. mansoni infection (i.e. positive
test result for POC-CCA and at least one positive
KK thick smear);
– be between 5 and 18 years of age;
– have a good medical condition, as determined by the
study physician based on biochemical, physical and
clinical indicators (i.e. absence of acute or severe
chronic disease);
– have received no PZQ treatment in the past 3
months; and
– be able and willing to provide multiple blood, stool
and urine samples during the study.
Exclusion criteria
A potential participant who does not meet the inclusion
criteria or who meets any of the following criteria will
be excluded from participation in this study:
– have a confirmed S. haematobium infection (as
determined by UF);
– have a known allergy to study medication (i.e. PZQ
and albendazole); and
– is pregnant (confirmed by pregnancy HCG test) or
lactating.
Procedures
Screening and informed consent
Individuals will be assessed for eligibility during a
2-week baseline screening. This will include public meet-
ings of awareness and health education, to allow all
members of the communities to be well informed on the
project. During these meetings, particular emphasis will
be placed on modes of transmission, associated patholo-
gies and risk factors related to schistosomiasis in par-
ticular and intestinal worms in general. After explaining
the purpose of the study in the local language, potential
participants will be asked to participate. After obtaining
oral and written assent from the children and signed
informed consent from their parents/legal guardians,
standard demographic and other characteristics (e.g.
age and sex) will be collected. Participants will be asked
to provide a urine sample which will be tested on site
immediately for Schistosoma infection by the POC-CCA
urine test as well as with UF. The initial screening by
POC-CCA will increase the likelihood of finding partici-
pants with a positive KK. Those with a positive
POC-CCA test result (scoring 1+ or higher) as well as a
negative UF result, will be asked to provide one stool
sample which will be examined for S.mansoni eggs by
triplicate KK. If at least one out of three smears is posi-
tive, the participant will be asked to undergo a bio-
logical, clinical and physical examination to determine
whether he/she is in good health. For the biological
exam, a blood sample will be obtained and tested for
haematological indicators, liver function and renal func-
tion parameters. A study physician will perform the
physical and clinical examinations, which will consist of
checking the participant’s physical condition as well as
determining if the participant has any chronic disease(s).
All participants who meet the inclusion criteria will be
enrolled and randomised.
Follow-up, sampling procedure and storage of samples
After randomisation, follow-up will take place on the se-
lected groups every week. Participants will be asked to
provide one urine sample every week and one stool sam-
ple every two weeks. A more detailed and schematic rep-
resentation is given in Fig. 2.
Each urine sample will be tested with the POC-CCA
test and KK examination will be performed on each
stool sample. An additional amount of sieved stool
(300–400 μL of volume) will be mixed with 1 mL of 96%
ethanol and stored for real-time PCR [32]. After every
visit, all collected samples will be taken to the laboratory
of the Centre Suisse de Recherches Scientifiques en Côte
d'Ivoire (CSRS)-Fairmed in Taabo for temporary storage.
Urine samples will be stored at − 20 °C and stool sam-
ples stored in ethanol. Once sample collection is com-
pleted, all samples will be transported from the
CSRS-Fairmed laboratory in Taabo to CSRS in Abidjan.
From all samples, one aliquot will be stored at CSRS in
Abidjan for long-term storage and one aliquot will be
sent to the Leiden University Medical Center (LUMC),
the Netherlands, for additional testing with the UCP-LF
CAA assay on urine samples and real-time PCR on stool
samples.
Diagnostics
As part of the inclusion-exclusion process, several tests
will be executed to determine eligibility for the study.
Absence of pregnancy, if appropriate, will be confirmed
with locally available pregnancy (HCG) tests. Infection
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with S. haematobium, will be determined by filtration of
10 mL of urine and microscopically examination, as de-
scribed previously [33]. Finally, to verify a potential par-
ticipant’s good health, a blood sample will be tested for
basic biochemical and haematological parameters (e.g.
urea, creatinine, liver enzymes and haemoglobin) in a
qualified local laboratory.
All urine samples will be tested at the CSRS-Fairmed
laboratory in Taabo using the POC-CCA assay (batch
no.: 170522062, Rapid Medical Diagnostics, Pretoria,
South Africa) as previously described [7, 17, 34]. At 20
min, valid tests will be scored as negative or positive ac-
cording to a set of 10 novel artificial cassettes with
inkjet-printed test lines representing negative and posi-
tive results depending on the intensity of the test line
(artificial score 1–10). These novel artificial scores will
be transformed into stratified positive scores of trace, 1
+, 2+ or 3+. All tests will be read independently by two
trained laboratory technicians. In case of discordant re-
sults, a third independent investigator will be consulted
and results will be discussed until agreement is reached
within 25min. UF will be performed on urine samples
collected at the final time point (week 8). Additionally,
all urine samples will be examined at the LUMC using
the UCP-LF CAA assay: a maximum of 2 mL urine will
be analysed with a cut-off threshold of 0.1 pg/ml, as pre-
viously described [19, 35]. CAA results will be reported
quantitatively in pg/ml.
From each stool sample triplicate KK thick smears
will be prepared at the laboratory of CSRS-Fairmed in
Taabo, using 41.7 mg templates, following standard
protocols [36]. Briefly, three KK thick smears (A, B
and C) will be prepared on microscope slides and ex-
amined quantitatively under a microscope by two in-
dependent, experienced laboratory technicians one
(A), two (B) and three (C) days after preparation. Re-
sults will be reported as eggs per slide and converted
to eggs per gram of faeces (EPG).
To detect the presence of Schistosoma DNA, real-time
PCR analysis will be performed on the ethanol-preserved
stool samples at the LUMC. Sample handling, DNA isolation
and PCR analysis will be performed as described previously
[37, 38]. The PCR output consists of a cycle-threshold (Ct)
value, which represented the amplification cycle in which the
level of fluorescent signal exceeded the background fluores-
cence, thereby indicating the amount of parasite-specific
DNA in the sample that was tested.
Treatment and adverse events
Treatment of participants with PZQ will be administered
by the study physician. The standard treatment group
will receive a standard dose of PZQ (single oral dose of
40 mg/kg) at week 0, while the intense treatment group
will receive PZQ at week 0, week 2, week 4 and week 6.
PZQ treatment will be given after a light meal, as rec-
ommended by WHO [2], to minimize potential adverse
events. The tablets will be administered under supervi-
sion of the study physician. If a participant vomits within
1.5 h following PZQ administration, another standard
dose of PZQ will be given.
Participants will be monitored for adverse events at 3
h and 24 h after PZQ administration. An adverse event
is defined as any undesirable experience occurring to a
participant during the study, whether or not considered
related to PZQ treatment. All adverse event intensities
will be assessed by the study physician, following local
guidelines and will be graded as mild, moderate or se-
vere. Additionally, to monitor the functioning of the vital
organs in the intense treatment group, participants will
be asked to provide blood samples at weeks 3 and 7,
Fig. 2 Schematic representation of follow-up, treatment and sampling procedures in the standard and intense treatment group.
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after the second and fourth treatment, respectively, to be
tested for haematological indicators, liver function and
renal function parameters.
At the end of the study all school-aged children in the
selected communities, including those who participated
in the study and those who participated in the baseline
screening but were not eligible to participate in the
study based on inclusion/exclusion criteria as well as
those who were not invited for baseline screening, will
be offered PZQ and albendazole treatment according to
and supplied by the PNLMTN-CP in Côte d’Ivoire.
Withdrawal
Participation is voluntary and participants can decide
not to continue their participation in the study at any
time for any reason if they wish to do so, without any
consequences. The principal investigator can also decide
to withdraw a participant from the study for any (ur-
gent) medical reasons.
Outcomes
The primary outcome for the study is:
 Difference in CR of one versus four standard doses
of PZQ (given two weeks apart) in participants
infected with S.mansoni, measured by KK at baseline
compared to week 8.
Secondary outcomes are:
 Difference in CR of one versus four standard doses
of PZQ in participants infected with S.mansoni as
measured by the different diagnostic tests at baseline
compared to week 8.
 Difference in CR of one versus two or three
standard doses of PZQ as measured by the different
diagnostic tests at baseline compared to weeks 4 or
6, respectively.
 Difference in intensity reduction rate (IRR) of one
versus four standard doses of PZQ (given two weeks
apart) on participants infected with S. mansoni
measured by the different diagnostic tests at baseline
compared to week 8.
 Difference in IRR between intervention and control
group of one versus two or three standard doses of
PZQ as measured by the different diagnostic tests at
baseline compared to weeks 4 or 6, respectively.
 Sensitivity and specificity of the different diagnostic
tests at different time points.
 Safety of repeated standard doses of PZQ.
Outcome measures
The CR is defined as the proportion of participants who
were S. mansoni egg positive at baseline and who became
S. mansoni egg negative at week 8, as determined by KK.
For the primary outcome, the CR in the standard treat-
ment group will be compared to the CR in the intense
treatment group. For the other diagnostic tests, the CR
will be the proportion of participants who were positive
by urine POC-CCA, urine UCP-LF CAA or stool PCR at
baseline and who became negative at week 8. Differences
between the standard and intense treatment group will be
compared. The overall IRR in the intense and standard
treatment groups will be calculated as the intensity of in-
fection at week 8 compared to the intensity of infection at
baseline, as determined by the different diagnostic tests
(intensity referring to egg counts for KK, artificial score
for POC-CCA, CAA level in pg/ml for UCP-LF CAA,
Ct-value for real-time PCR). Additionally, the CR and IRR
will be determined at intermediate time points after one
versus two and one versus three standard doses of PZQ.
All adverse events occurring within 24 h after PZQ
treatment will be recorded to evaluate the safety and tol-
erability of repeated PZQ treatment.
Randomisation and blinding
All participants will be randomised at baseline in a 1:1
ratio, by an independent statistician. Local nurses and
physicians will not be blinded to treatment. Study
personnel, laboratory technicians and investigators will
be blinded. Data analysis will be performed blinded to
the intervention.
Sample size calculation
The sample size estimation is based on the difference in
CR of one versus four repeated standard doses of PZQ
measured with KK 8 weeks after treatment. Based on
previous, data we assume a CR of 66% after one stand-
ard dose of PZQ [11] and aim for an increased CR of
98.7% after four repeated doses of PZQ, leading to a
sample size of 30 participants per group, with a power of
90% and a level of significance of 5% (2-tail) [39]. Be-
cause we anticipate a considerable loss to follow-up, we
aim to include approximately 100 participants in each
group, hence 200 participants in total.
Assuming a S. mansoni prevalence of approximately
25% by KK (unpublished data, Taabo HDSS survey Feb-
ruary 2016) it is estimated that at least 1000 children will
have to be screened to obtain a minimum of 200 KK
positives in the selected region.
Data management and statistical analysis
Each participant will be given a unique study identifi-
cation number. Data will be collected using paper-
based case report forms (CRFs) and will be double
entered and managed by well-trained data entry
personnel using the REDCap electronic data capture
tools hosted at the Leiden University Medical Center, the
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Netherlands, via Emory University, Atlanta, GA, USA
[40].
All analyses will be conducted blinded to the treatment
allocations and will be performed using STATA version 12
(StataCorp; College Station, TX, USA) or IBM Statistical
Package for Social Sciences version 23 (SPSS Inc., Chicago,
Illinois, USA) or R language (R Foundation for Statistical
Computing; Vienna, Austria). Response and dropout rates
will be assessed and reported. Demographics and outcome
parameters will be summarised using descriptive summary
measures, expressed as mean (standard deviation) or me-
dian (interquartile range) for continuous variables depend-
ing on whether the data are normally distributed and
frequencies (percentage) for categorical variables. The pro-
portion of participants positive for intestinal schistosomiasis
will be calculated as the proportion of participants who
tested positive at various time points (e.g. baseline, week 1,
week 2, etc.). These percentages positive for schistosomiasis
will be reported separately for each diagnostic test. Baseline
characteristics between the control and intervention groups
will be compared using the X2 test for categorical variables
and t-test or Mann-Whitney U for continuous variables de-
pending on the distribution of the data.
For the primary and secondary outcomes, a repeated
measurements analysis approach will be used [41]. With
this approach, the correlation between the measure-
ments collected from the same participant over time will
be modelled using properly chosen correlation matrices.
Based on this analysis the proportions cured at different
time points will be estimated and differences between
the intense and standard treatment group will be tested
for statistical significance. Similarly, for the IRR the pro-
gression of the reduction in intensity will be estimated
and differences between the two groups at different time
points will be tested for statistical significance. This
model-based approach is becoming a more popular
method to properly analyse longitudinal data on treat-
ment efficacy of PZQ among individuals as well as
among groups of individuals [42–44]. Transformation of
data will be applied if needed. The model will be ad-
justed for covariates such as age and sex. Although the
assumption will be made that missing data will be miss-
ing at random, reasons for individuals missing treatment
at each time-point will be recorded.
In the absence of a true ‘gold’ standard, the sensitivity
and specificity for KK, POC-CCA, UCP-LF CAA and
PCR will be estimated by using an imperfect ‘gold’ stand-
ard (based on assumptions of 100% specificity for KK,
CAA and PCR, similarly to Knopp et al., 2015 [45]) as
well as by using latent class analysis (LCA). LCA uses all
available data to estimate the proportion of true positives
that test positive for each test (i.e. the sensitivity of each
test), the proportion of true negatives that test negative
for each test (i.e. the specificity of each test), and the
proportion of individuals truly positive in the study
population (i.e. the infection prevalence within the study
population), as described previously [46, 47]. The sensi-
tivity, specificity, positive predictive value (PPV) and
negative predictive value (NPV) of all diagnostic tests
will be calculated with 95% confidence intervals (CIs).
For all analysis, a p value of < 0.05 will be taken as the
level for statistical significance.
Data safety and monitoring board
An independent data safety and monitoring board
(DSMB) has been established which will review safety
data from the first and third treatment during the study
and provide recommendations to the sponsor concern-
ing the continuation of the study.
Ethical considerations
The study is registered at ClinicalTrials.gov (reference num-
ber NCT02868385) as well as at the EU Clinical Trials Regis-
ter (EudraCT, reference number 2016–003017-10) and will
be conducted in accordance with the latest version of the
Helsinki Declaration. The study has been approved by the
National Ethics Committee of the Ministry of Health in Côte
d’Ivoire (CNESVS, registration number 091–18/MSHP/
CNESVS-km, 27 June 2018) as well as by the Direction de la
Pharmacie, du Médicament et des Laboratoires de Côte
d’Ivoire (DPML, registration number 99433-/MSHP/DGS/
DPML/DAR and clinical trial number ECCI00618, 22 Octo-
ber 2018) and has been reviewed by the Ethics Committee of
the Leiden University Medical Center in the Netherlands
without any objections (CME, registration number P16.254,
11 January 2017). This study protocol, including the statis-
tical analysis section, has been written before start of the trial.
The data analysis of the main publication will follow this
plan. The SPIRIT protocol checklist is given in Additional
file 1.
Discussion
The RePST trial is the first and currently the only clin-
ical trial that will investigate the efficacy of four repeated
standard doses of PZQ on the clearance of S. mansoni in
a randomised trial design. Efficacy will be assessed by
using several diagnostic techniques, including real-time
PCR and the ultra-sensitive UCP-LF CAA assay. By
using an extensive panel of diagnostics in a frequent
post-treatment sampling schedule, this study is the first
of its kind to comprehensively assess the efficacy of sin-
gle as well as repeated doses of PZQ.
This study is a proof of concept study to determine
the efficacy of repeated PZQ treatment in an endemic
setting. The context is to provide evidence and tools for
evaluating current schistosomiasis control approaches,
as well as input for developing new strategies for indi-
vidual cure and transmission interruption rather than
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population-wide morbidity control. Clearly this study is
not aiming to design repeated PZQ treatment schedules
for implementation in large-scale control programmes.
Results will also prove to be highly relevant in individual
test-and-treat approaches using non-invasive POC diag-
nostics, even in non-endemic settings. The in-depth ana-
lysis and validation of different diagnostic tools (before
and) after treatment is essential to determine the effect
of PZQ on different parasite-related parameters provid-
ing additional information on CRs, re-emergence of in-
fections, and even on transmission potential. Accurate
diagnosis of light intensity infections (after intensive
chemotherapy) will also be crucial in the light of elimin-
ation of schistosomiasis now being a target in several en-
demic countries [48, 49] and clearly advocated by WHO
[9].
Trial status
This open-label, randomised controlled trial has started
recruitment in October 2018. We envisage the sample
collection period to be finished by the end of 2018, and
sample processing and testing at the LUMC to start
early 2019.
Additional file
Additional file 1: SPIRIT checklist for the RePST trial, indicating which
manuscript page contains each element of the study protocol. (DOX 135
kb)
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